Next Article in Journal
Quality of Life in Older Patients after a Heart Failure Hospitalization: Results from the SENECOR Study
Next Article in Special Issue
Is Prehospital Assessment of qSOFA Parameters Associated with Earlier Targeted Sepsis Therapy? A Retrospective Cohort Study
Previous Article in Journal
Psychological Effects and Medication Adherence among Korean Patients with Inflammatory Bowel Disease during the Coronavirus Disease 2019 Pandemic: A Single-Center Survey
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 11
10.3390/jcm11113031
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Impact of Myosteatosis Percentage on Short-Term Mortality in Patients with Septic Shock

by
June-sung Kim
1,
Jiyeon Ha
2,
Youn-Jung Kim
1,
Yousun Ko
3,
Taeyong Park
4,
Kyung Won Kim
4 and
Won Young Kim
1,*
1
Department of Emergency Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea
2
Department of Radiology, Hallym University College of Medicine, Kangdong Seong-Sim Hospital, Seoul 05355, Korea
3
Biomedical Research Center, Asan Institute for Life Science, Asan Medical Center, Seoul 05505, Korea
4
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(11), 3031; https://doi.org/10.3390/jcm11113031
Submission received: 6 April 2022 / Revised: 25 May 2022 / Accepted: 25 May 2022 / Published: 27 May 2022
(This article belongs to the Special Issue Clinical Updates in Sepsis and Septic Shock)
Browse Figures
Review Reports Versions Notes

Abstract

:
The impact of myosteatosis on septic patients has not been fully revealed. The aim of the study was to evaluate the impact of the myosteatosis area and percentage on the 28-day mortality in patients with septic shock. We conducted a single center, retrospective study from a prospectively collected registry of adult patients with septic shock who presented to the emergency department and performed abdominal computed tomography (CT) from May 2016 to May 2020. The myosteatosis area defined as the sum of low attenuation muscle area and intramuscular adipose tissue at the level of the third lumbar vertebra was measured by CT. Myosteatosis percentages were calculated by dividing the myosteatosis area by the total abdominal muscle area. Of the 896 patients, 28-day mortality was 16.3%, and the abnormal myosteatosis area was commonly detected (81.7%). Among variables of body compositions, non-survivors had relatively lower normal attenuation muscle area, higher low attenuation muscle area, and higher myosteatosis area and percentage than that of survivors. Trends of myosteatosis according to age group were different between the male and female groups. In subgroup analysis with male patients, the multivariate model showed that the myosteatosis percentage (adjusted OR 1.02 [95% CI 1.01–1.03]) was an independent risk factor for 28-day mortality. However, this association was not evident in the female group. Myosteatosis was common and high myosteatosis percentage was associated with short-term mortality in patients with septic shock. Our results implied that abnormal fatty disposition in muscle could impact on increased mortality, and this effect was more prominent in male patients.

1. Introduction

Sepsis and septic shock are still leading causes of in-hospital death in worldwide [1]. Because of its heterogeneity, identifying which patients are at high risk of poor outcomes is needed for personalized management. The Third International Consensus Definitions for Sepsis and Septic Shock proposed to use the Sequential Organ Failure Assessment (SOFA) score for screening and prognostication [2]. However, assessing only organ dysfunction could not predict poor outcomes effectively, and intensive research efforts had tried to find out other risk factors for septic shock. In this context, focus was placed on body composition as a potential biomarker to predict clinical outcomes [3,4,5]. The body composition measurement could be carried out using computed tomography (CT) performed as a routine clinical practice [6,7,8,9]. To find out the source of infection and pre-intervention workup, abdominal CT evaluation in patients with septic shock is prevalent.
We previously reported that a decreased skeletal muscle index was related with poor outcomes in cancer patients with septic shock [10]. However, the skeletal muscle index is limited in that it only reflects muscle quantity, not function or strength [10]. Recent studies demonstrated that muscle quality and strength are associated with the degree of fatty infiltration or fatty degeneration called myosteatosis [11,12]. Myosteatosis, which once referred to age-related excessive fatty disposition, is now considered to be a pathological phenomenon and can be estimated by the attenuation of skeletal muscle Hounsfield Units (HU) on a CT scan [13,14]. Although impact of myosteatosis in patients with malignancy, liver cirrhosis, and inflammatory bowel disease had been reported, little is known about the impact of myosteatosis on the outcome of the patients with septic shock [15,16,17,18]. Recent studies with critically ill patients proved that abnormal fat disposition could be related with poor prognosis due to an overactivated inflammatory response [19,20,21]. However, their sample sizes were relatively small and detected myosteatosis with different definitions. Furthermore, mean muscle attenuation for the entire muscle area (MA) could be inaccurate for detecting the exact amount of myosteatosis because the proportion of myosteatosis might be markedly dependent on the entire MA [22]. Therefore, we tried to evaluate the prevalence of abnormal myosteatosis percentages, defined as myosteatosis area normalized by total abdominal MA, and the association between myosteatosis percentage and short-term mortality in patients with septic shock.
The objective of this study was to determine the prognostic significance of myosteatosis percentage in patients with septic shock.

2. Materials and Methods

2.1. Study Design and Population

This single center, observational, prospectively collected registry-based study was performed at the emergency department (ED) of a tertiary, university-affiliated hospital in Seoul, Korea, with an annual census of approximately 120,000 visits between May 2016 and May 2020. ED of the study facility have enrolled all adult (≥18 years old) patients with suspected or confirmed septic shock in the registry to monitor and improve outcomes [23]. Shock due to suspected infection was screened and enrolled to the registry by the emergency physicians on duty. We used a definition of septic shock as refractory low blood pressure (mean arterial pressure ≤ 65 mmHg) requiring vasopressors in spite of sufficient volume infusion or a serum lactate level ≥ 4 mmol/L, based on previous definition [24,25]. Patients were excluded in the registry if they were transferred from other hospital after initial resuscitation, were transferred to other hospital, had “do-not-resuscitation” order, refused to manage, developed septic shock 6 or more hours after ED arrival, or do not required vasopressor after fluid loading. All enrolled patients were equally treated with protocol-driven resuscitation following the current guidelines and bundles of the Surviving Sepsis Campaign [24].
This study included registry-enrolled patients who underwent abdominal CT examination, which had been taken for diagnostic purposes, at ED presentation. The institutional review board of the study facility approved this study (IRB number: 2021-0392) and waived the requirement for informed consent because of the retrospective characteristics.

2.2. Measures

Demographic data, focus of infection, SOFA score, acute physiology and chronic health evaluation (APACHE) II score, and initial lactate level were extracted from the registry. SOFA and APACHE II scores were calculated using the worst variables during the initial 24 h after ED presentation. The primary outcome was 28-day mortality.
Electronic medical records were used to collect additional data to assess body morphometry, such as body weight, height, and the presence of abdominal CT scan. Body mass index (BMI) was computed as the weight in kilograms divided by the height squared in meters (kg/m2). The body composition and quality, including subcutaneous fat area (SFA), visceral fat area (VFA), skeletal muscle area (SMA), normal attenuation muscle area (MA), intra-muscular adipose tissue area, and low attenuation MA, were assessed at the third lumbar (L3) vertebral level of abdominal CT scan performed at ED presentation using a previously developed web-based iAID toolkit [26]. Briefly, this algorithm selected a single axial image at the inferior endplate level of the L3 vertebra at the portal venous phase and segmented abdominal body compartments into three areas (i.e., total abdominal MA, SFA, and VFA). Moreover, total abdominal MA was divided into 3 muscle components using the pixel-wise measurement of CT density with the following range of HU for each component: normal attenuation MA with +30 HU to +150 HU, low attenuation MA with =29 HU to +29 HU, and intra-muscular adipose tissue area with −190 HU to −30 HU [13,27]. The accuracy of the generated muscle quality map composed of normal attenuation MA, low attenuation MA, and intra-muscular adipose tissue area was confirmed by a board-certified abdominal radiologist by comparing the original CT image and the muscle quality map image (Figure 1).
The skeletal muscle index (SMI) was calculated as the SMA which was defined as the sum of normal attenuation MA and low attenuation MA in cm2 divided by the height squared in meters (cm2/m2) [28]. Sarcopenia, diagnosed based on the abnormal SMI, was diagnosed based on the low muscle mass and impaired function, defined using sex-specific SMIs: <43 cm2/m2 for a BMI <25 kg/m2, <53 cm2/m2 for a BMI or 25 kg/m2 or more, and <41 cm2/m2 regardless of the BMI for females in a past study [28,29]. Myosteatosis was defined as the sum of low attenuation MA and intra-muscular adipose tissue area. Furthermore, the myosteatosis percentage was calculated as the myosteatosis area divided by the total abdominal MA to adjust the effect of total muscle amount. Abnormal myosteatosis area according to both age and sex was defined as in a previous report with healthy Asian populations [26].

2.3. Statistical Analyses

Descriptive statistics were stratified by 28-day all-cause mortality (i.e., survivor and non-survivor). Baseline demographics, clinical characteristics, laboratory results, and variables relating to body composition are presented as the frequency and percentage for categorical and median with interquartile range (IQR) for continuous variables. The Kolmogorov–Smirnov test was used to find out the normality of the distribution. Categorical variables were analyzed using Chi-squared or Fisher’s exact tests. We also evaluated the association between the skeletal muscle index, myosteatosis percentage and 28-day mortality separately according to gender. Univariate logistic regression tests were conducted with potential risk factors, which showed differences between survivors and non-survivors. Multivariate logistic regression was conducted with the variables that had previously well-known risk factors, such as age, infection focuses, comorbidities, lactate levels, SOFA, and APACHE score, with significantly different (p-values < 0.1) in the univariate logistic regression analysis [1,2,23]. Multicollinearity among variables was checked by using variance inflation factors before performing the multiple regression model. Moreover, we conducted subgroup analysis according to each gender because the previous report presented that the distributions of most body compositions were different between genders (10). We considered p-values less than 0.05 as statistically significant. Analyses were performed using SPSS Statistics for Mac, version 26 (IBM Corp., Armonk, NY, USA) and R version 3.5.0 (R foundation for Statistical Computing, Vienna, Austria).

3. Results

Among 1160 patients with septic shock in the registry, 896 (77.2%) patients who underwent an abdominal CT at ED were included. The rate of 28-day mortality was 16.3% (n = 146) (Figure 2).

3.1. Baseline Characteristics of the Cohort Population

The baseline characteristics of the study population are presented in Table 1. The median age was 67.0 (58.0–75.0) years with male predominance (58.8%). Non-survivors had higher proportions of chronic pulmonary disease (8.9 vs. 4.5%), malignancy (50.7 vs. 40.4%), hematologic disorder (11.6 vs. 5.5%), and liver cirrhosis (21.2 vs. 14.4%) than that of survivors. Except for unknown focus and blood stream, most sites of infection were significantly different between groups. Non-survivors showed more frequent infection in lung (24.0 vs. 14.9%) and intra-abdominal sources (22.6 vs. 14.4%) but less in urinary tract (9.6 vs. 16.9%) and hepato-biliary-pancreas (32.2 vs. 41.5%) than survivors. In addition, the non-survivor group had significantly higher lactate level, SOFA score, and APACHE scores than the survivor group. Based on diagnosing with current cut-off values, sarcopenia (63.3%) and myosteatosis (81.7%) were common in the study population, but there were no significant differences between the two groups. Separate demographics and clinical characteristics of each gender were showed in supplementary tables (see Supplementary Tables S1 and S2).

3.2. Distribution of Myosteatosis Area and Percentage

Figure 3 illustrates the median of the myosteatosis area and percentage according to age groups for male and female patients. In the total population, the myosteatosis area had a positive correlation with age. Non-survivors had a larger area than survivors. These trends became clearer after converting myosteatosis percentages. The trends of the myosteatosis area and percentage according to age groups showed differences between the male and female groups. Differences between survivors and non-survivors were prominent in the forties to fifties in the female group and sixties to seventies in the male group.
The detailed body morphometry in the overall patients and by sex are presented in Table 2. Comparing with female, body compositions of male tent to show significant differences between survivor and non-survivor groups. Male non-survivors had smaller SMA (114.4 vs. 120.3 cm2), smaller normal attenuation MA (60.3 vs. 73.3 cm2), smaller total abdominal MA (128.8 vs. 138.4 cm2), larger low attenuation MA (53.8 vs. 49.0 cm2), and larger myosteatosis percentage (51.8 vs. 46.1%). However, these differences did not appear in female patients except for low attenuation MA (54.3 vs. 46.5 cm2) and myosteatosis percentage (69.1 vs. 60.9%).

3.3. Risk Factors of Short-Term Mortality

The multivariable logistic regression analyses for male patients showed that the lower SMI (adjusted OR 0.96; 95% CI 0.93–0.98; p = 0.03) and higher myosteatosis percentage (adjusted OR 1.03; 95% CI 1.01–1.05; p = 0.04) were independently associated with a higher 28-day mortality (Table 3). Meanwhile, myosteatosis percentages were not associated with 28-day mortality in female.

4. Discussion

In this study of body composition involving patients with septic shock, in which SMI was included as independent parameter, the myosteatosis percentage was the parameter that was associated with short-term survival. Our results implied that a high fatty disposition in muscle is associated with increased mortality in patients with septic shock and could be a useful prognostic factor in clinical practice. In addition, this effect was more prominent in male than female patients.
Myosteatosis is an abnormal fat depot that increases with aging and is identified to negatively correlate with muscle strength and mobility and impede metabolism [30]. Our result shows that myosteatosis is predominant in patients with septic shock. A recent review reported that the overall prevalence of myosteatosis in critically ill patients ranged from 25% to 40% [17,31]. This relatively low prevalence was attributed by employing a different definition of myosteatosis from that of the present study. Traditionally, myosteatosis was quantified by using the mean muscle density of the total abdominal muscle [22]. This definition could be inaccurate to detect the extent of myosteatosis and might under- or over-estimate the proportion of the ectopic fat deposit. Moreover, most studies set single cut-off values (e.g., below 40 HU) for detecting myosteatosis [22]. However, previous research with healthy population showed that the degree of myosteatosis was totally different according to age and sex. In this manner, we measured the direct area of normal attenuation MA and intra-muscular adipose tissue and diagnosed myosteatosis based on previously reported cut-off values according to age and sex [26]. Interestingly, this method revealed that a surprising portion of patients with septic shock had myosteatosis and the differences were largely due more to normal attenuation MA than to intra-muscular adipose tissue in both male and female groups.
We identified the statistical differences of myosteatosis percentages between 28-day survivors and non-survivors for both male and female patients. This scaling has a definite physiological basis that the myosteatosis area was largely affected by total abdominal MA. Although causality can be inferred only from direct controlled trials, we found that myosteatosis could be a surrogate marker of short-term survival among patients with septic shock. This result is consistent with that of a previous study that the progression of myosteatosis contributed to the development of sepsis [32]. Furthermore, a recent longitudinal laboratory study with mice reported that the amount of myosteatosis had a positive correlation with the severity of inflammation in non-alcoholic fatty liver disease [33]. The exact pathologic mechanism has not been completely revealed, but it seems to be the result of a complex cascade involving dysregulation of inflammatory response by excess adipose tissue [34]. A recent pre-clinic study also showed that worse muscle quality was related with abnormally higher levels of expression of inflammatory markers, suggesting the existence of abnormal response to pathogen [35].
Although the myosteatosis percentages were different between survivors and non-survivors, only the male group showed that this variable was an independent risk factor for predicting 28-day mortality. Sex-specific differences have been largely reported for fat distribution, properties, secretory function, and fatty acid handling in healthy participants and preclinical models [36]. The exact mechanism of this dimorphism is not yet elucidated; however, a plausible explanation is that there is a different proportion of sex hormones because sex steroids seem to play as endogenous modulators of development and function, and also influence the distribution of fat [37,38]. Another possible reason was that the study population consisted of an older age group (i.e., above 70% of patients were above sixty) so that differences in myosteatosis percentage were less evident between survivors and non-survivors in the female group. This proportion of age group might affect the results of the study. A further study with a larger sample size could reveal differences between gender groups.
Our study has several limitations. First, because the single-center retrospective design is in South Korea, it might be hard to generalize to other populations. Racial-ethnic differences in body composition have been widely reported [39]. Because there were no definite cut-off values of myosteatosis area or percentage, we diagnosed myosteatosis based on a previous report and this could over- or under-estimate the prevalence [26]. Second, we analyzed the patients with septic shock who clinically recorded CT images. Therefore, baseline characteristics of the study population showed a relatively low proportion of lung infection and a high proportion of abdominal infection. The relatively low mortality (16.5%) in the study was attributed to this selection bias. A further, well-designed, prospective study would be necessary to overcome this limitation. Third, although we tried to adjust the confounding factors, hidden confounders, including supplemental nutrients during the treated period, could affect mortality.
In conclusion, most patients with septic shock had myosteatosis, which was independently associated with 28-day mortality. Even though this association was evident in the male group, myosteatosis could be a useful prognostic marker for mortality in patients with septic shock.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11113031/s1, Table S1: Baseline characteristics of the male patients, Table S2: Baseline characteristics of the female patients.

Author Contributions

Conceptualization, W.Y.K. and J.-s.K.; validation, Y.-J.K. and W.Y.K.; formal analysis, J.-s.K. and J.H.; data curation, Y.K., T.P. and K.W.K.; writing—original draft preparation, J.-s.K.; writing—review and editing, J.H., J.-s.K. and J.H.; visualization, J.-s.K. and Y.-J.K.; supervision, W.Y.K. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C1216) and supported by Better Life and Health Corperation (BL&H) (grant number: A20192926).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Asan Medical Center (No. 2021-0392).

Informed Consent Statement

Patient consent was waived due to the retrospective design.

Data Availability Statement

Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Colombara, D.V.; Ikuta, K.S.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the global burden of disease study. Lancet 2020, 395, 200–211. [Google Scholar] [CrossRef] [Green Version]
  2. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef]
  3. Akahori, T.; Sho, M.; Kinoshita, S.; Nagai, M.; Nishiwada, S.; Tanaka, T.; Tamamoto, T.; Ohbayashi, C.; Hasegawa, M.; Kichikawa, K.; et al. Prognostic significance of muscle attenuation in pancreatic cancer patients treated with neoadjuvant chemoradiotherapy. World J. Surg. 2015, 39, 2975–2982. [Google Scholar] [CrossRef] [PubMed]
  4. Chu, M.P.; Lieffers, J.; Ghosh, S.; Belch, A.; Chua, N.S.; Fontaine, A.; Sangha, R.; Turner, R.A.; Baracos, V.E.; Sawyer, M.B. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. J. Cachexia Sarcopenia Muscle 2017, 8, 298–304. [Google Scholar] [CrossRef]
  5. Dijksterhuis, W.P.M.; Pruijt, M.J.; Woude, S.O.; Klaassen, R.; Kurk, S.A.; Oijen, M.G.H.; Laarhoven, H.W.M. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J. Cachexia Sarcopenia Muscle 2019, 10, 199–206. [Google Scholar] [CrossRef] [Green Version]
  6. Park, J.; Gil, J.R.; Shin, Y.; Won, S.E.; Huh, J.; You, M.-W.; Park, H.J.; Sung, Y.S.; Kim, K.W. Reliable and robust method for abdominal muscle mass quantification using CT/MRI: An explorative study in healthy subjects. PLoS ONE 2019, 14, e0222042. [Google Scholar] [CrossRef] [PubMed]
  7. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Writing group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised european consensus on definition and diagnosis. Age Ageing 2018, 48, 16–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Shen, W.; Punyanitya, M.; Wang, Z.; Gallagher, D.; St.-Onge, M.-P.; Albu, J.; Heymsfield, S.B.; Heshka, S. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J. Appl. Physiol. 2004, 97, 2333–2338. [Google Scholar] [CrossRef] [Green Version]
  9. Lee, K.; Shin, Y.; Huh, J.; Sung, Y.S.; Lee, I.-S.; Yoon, K.-H.; Kim, K.W. Recent issues on body composition imaging for sarcopenia evaluation. Korean J. Radiol. 2018, 20, 205. [Google Scholar] [CrossRef]
  10. Kim, Y.-J.; Seo, D.-W.; Kang, J.; Huh, J.W.; Kim, K.W.; Kim, W.Y. Impact of body composition status on 90-day mortality in cancer patients with septic shock: Sex differences in the skeletal muscle index. J. Clin. Med. 2019, 8, 1583. [Google Scholar] [CrossRef] [Green Version]
  11. Kaibori, M.; Ishizaki, M.; Iida, H.; Matsui, K.; Sakaguchi, T.; Inoue, K.; Mizuta, T.; Ide, Y.; Iwasaka, J.; Kimura, Y.; et al. Effect of intramuscular adipose tissue content on prognosis in patients undergoing hepatocellular carcinoma resection. J. Gastrointest. Surg. 2015, 19, 1315–1323. [Google Scholar] [CrossRef] [PubMed]
  12. Miljkovic, I.; Cauley, J.A.; Wang, P.Y.; Holton, K.F.; Lee, C.G.; Sheu, Y.; Barrett-Connor, E.; Hoffman, A.R.; Lewis, C.B.; Orwoll, E.S.; et al. Osteoporotic Fractures in Men (MrOS) Research Group. Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes. Obesity 2013, 21, 2118–2125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Aubrey, J.; Esfandiari, N.; Baracos, V.E.; Buteau, F.A.; Frenette, J.; Putman, C.T.; Mazurak, V.C. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 2014, 210, 489–497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Miljkovic, I.; Zmuda, J.M. Epidemiology of myosteatosis. Curr. Opin. Clin. Nutr. 2010, 13, 260–264. [Google Scholar] [CrossRef]
  15. Okumura, S.; Kaido, T.; Hamaguchi, Y.; Kobayashi, A.; Shirai, H.; Fujimoto, Y.; Iida, T.; Yagi, S.; Taura, K.; Hatano, E.; et al. Impact of skeletal muscle mass, muscle quality, and visceral adiposity on outcomes following resection of intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2017, 24, 1037–1045. [Google Scholar] [CrossRef]
  16. Rier, H.N.; Jager, A.; Sleijfer, S.; van Rosmalen, J.; Kock, M.C.J.M.; Levin, M.-D. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 2017, 31, 9–15. [Google Scholar] [CrossRef]
  17. Bhanji, R.A.; Moctezuma-Velazquez, C.; Duarte-Rojo, A.; Ebadi, M.; Ghosh, S.; Rose, C.; Montano-Loza, A.J. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol. Int. 2018, 12, 377–386. [Google Scholar] [CrossRef]
  18. O’Brien, S.; Kavanagh, R.G.; Carey, B.W.; Maher, M.M.; O’Connor, O.J.; Andrews, E.J. The impact of sarcopenia and myosteatosis on postoperative outcomes in patients with inflammatory bowel disease. Eur. Radiol. Exp. 2018, 2, 37. [Google Scholar] [CrossRef]
  19. Moisey, L.L.; Mourtzakis, M.; Cotton, B.A.; Premji, T.; Heyland, D.K.; Wade, C.E.; Bulger, E.; Kozar, R.A. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit. Care 2013, 17, R206. [Google Scholar] [CrossRef] [Green Version]
  20. Mueller, N.; Murthy, S.; Tainter, C.R.; Lee, J.; Richard, K.; Fintelmann, F.J.; Grabitz, S.D.; Timm, F.P.; Levi, B.; Kurth, T.; et al. Can sarcopenia quantified by ultrasound of the rectus femoris muscle predict adverse outcome of surgical intensive care unit patients and frailty? A prospective, observational cohort study. Ann. Surg. 2016, 6, 1116–1124. [Google Scholar] [CrossRef] [Green Version]
  21. Shashaty, M.G.S.; Kalkan, E.; Bellamy, S.L.; Reilly, J.P.; Holena, D.N.; Cummins, K.; Lanken, P.N.; Feldman, H.I.; Reilly, M.P.; Udupa, J.K.; et al. Computed tomography–defined abdominal adiposity is associated with acute kidney injury in critically ill trauma patients. Crit. Care Med. 2014, 42, 1619–1628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Aleixo, G.F.P.; Shachar, S.S.; Nyrop, K.A.; Muss, H.B.; Castillo, L.M.; Williams, G.R. Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Crit. Rev. Oncol. Hemat. 2020, 145, 102839. [Google Scholar] [CrossRef] [PubMed]
  23. Kim, J.; Kim, Y.-J.; Kim, W.Y. Characteristics and clinical outcomes of culture-negative and culture-positive septic shock: A single-center retrospective cohort study. Crit. Care 2021, 25, 11. [Google Scholar] [CrossRef] [PubMed]
  24. Rhodes, A.; Evans, L.E.; Alhazzani, W.; Levy, M.M.; Antonelli, M.; Ferrer, R.; Kumar, A.; Sevransky, J.E.; Sprung, C.L.; Nunnally, M.E.; et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 2017, 45, 486–552. [Google Scholar] [CrossRef] [PubMed]
  25. Casserly, B.; Phillips, G.S.; Schorr, C.; Dellinger, R.P.; Townsend, S.R.; Osborn, T.M.; Reinhart, K.; Selvakumar, N.; Levy, M.M. Lactate measurements in sepsis-induced tissue hypoperfusion. Crit. Care Med. 2015, 43, 567–573. [Google Scholar] [CrossRef] [PubMed]
  26. Kim, D.W.; Kim, K.W.; Ko, Y.; Park, T.; Khang, S.; Jeong, H.; Koo, K.; Lee, J.; Kim, H.-K.; Ha, J.; et al. Assessment of myosteatosis on computed tomography by automatic generation of a muscle quality map using a web-based toolkit: Feasibility study. JMIR Med. Inform. 2020, 8, e23049. [Google Scholar] [CrossRef]
  27. Poltronieri, T.S.; Paula, N.S.; Chaves, G.V. Assessing skeletal muscle radiodensity by computed tomography: An integrative review of the applied methodologies. Clin. Physiol. Funct. Imaging 2020, 40, 207–223. [Google Scholar] [CrossRef] [PubMed]
  28. Prado, C.M.; Lieffers, J.R.; McCargar, L.J.; Reiman, T.; Sawyer, M.B.; Martin, L.; Baracos, V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 2008, 9, 629–635. [Google Scholar] [CrossRef]
  29. Muscaritoli, M.; Anker, S.D.; Argilés, J.; Aversa, Z.; Bauer, J.M.; Biolo, G.; Boirie, Y.; Bosaeus, I.; Cederholm, T.; Costelli, P.; et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “Cachexia-Anorexia in Chronic Wasting Diseases” and “Nutrition in Geriatrics”. Clin. Nutr. 2010, 29, 154–159. [Google Scholar] [CrossRef]
  30. Correa-de-Araujo, R.; Addison, O.; Miljkovic, I.; Goodpaster, B.H.; Bergman, B.C.; Clark, R.V.; Elena, J.W.; Esser, K.A.; Ferrucci, L.; Harris-Love, M.O.; et al. Myosteatosis in the context of skeletal muscle function deficit: An interdisciplinary workshop at the national institute on aging. Front. Physiol. 2020, 11, 963. [Google Scholar] [CrossRef]
  31. Montano-Loza, A.J.; Angulo, P.; Meza-Junco, J.; Prado, C.M.M.; Sawyer, M.B.; Beaumont, C.; Esfandiari, N.; Ma, M.; Baracos, V.E. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J. Cachexia Sarcopenia Muscle 2016, 7, 126–135. [Google Scholar] [CrossRef] [PubMed]
  32. Nachit, M.; Rudder, M.D.; Thissen, J.; Schakman, O.; Bouzin, C.; Horsmans, Y.; Velde, G.V.; Leclercq, I.A. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J. Cachexia Sarcopenia Muscle 2021, 12, 144–158. [Google Scholar] [CrossRef] [PubMed]
  33. Reisinger, K.W.; van Vugt, J.L.A.; Tegels, J.J.W.; Snijders, C.; Hulsewé, K.W.E.; Hoofwijk, A.G.M.; Stoot, J.H.; Meyenfeldt, M.F.V.; Beets, G.L.; Derikx, J.P.M.; et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann. Surg. 2015, 261, 345–352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Zoico, E.; Corzato, F.; Bambace, C.; Rossi, A.P.; Micciolo, R.; Cinti, S.; Harris, T.B.; Zamboni, M. Myosteatosis and myofibrosis: Relationship with aging, inflammation and insulin resistance. Arch. Gerontol. Geriat. 2013, 57, 411–416. [Google Scholar] [CrossRef] [Green Version]
  35. Santosa, S.; Hensrud, D.D.; Votruba, S.B.; Jensen, M.D. The influence of sex and obesity phenotype on meal fatty acid metabolism before and after weight loss. Am. J. Clin. Nutr. 2008, 4, 1134–1141. [Google Scholar] [CrossRef]
  36. White, U.A.; Tchoukalova, Y.D. Sex Dimorphism and depot differences in adipose tissue function. Biochim. Biophys. Acta (BBA)—Mol. Basis Dis. 2014, 1842, 377–392. [Google Scholar] [CrossRef] [Green Version]
  37. Schorr, M.; Dichtel, L.E.; Gerweck, A.V.; Valera, R.D.; Torriani, M.; Miller, K.K.; Bredella, M.A. Sex differences in body composition and association with cardiometabolic risk. Biol. Sex. Differ. 2018, 9, 28. [Google Scholar] [CrossRef]
  38. Taaffe, D.R.; Cauley, J.A.; Danielson, M.; Nevitt, M.C.; Lang, T.F.; Bauer, D.C.; Harris, T.B. Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: The health, aging, and body composition study. J. Bone Miner. Res. 2001, 7, 1343–1352. [Google Scholar] [CrossRef]
  39. Zhuang, C.-L.; Shen, X.; Huang, Y.-Y.; Zhang, F.-M.; Chen, X.-Y.; Ma, L.-L.; Chen, X.-L.; Yu, Z.; Wang, S.-L. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: A propensity score–matched analysis from a large-scale cohort. Surgery 2019, 166, 297–304. [Google Scholar] [CrossRef]
Jcm 11 03031 g001 550
Figure 1. Example of body composition measurements. Muscle quality map generation using a web-based toolkit. After dividing body composition into 3 parts (i.e., subcutaneous fat, visceral fat, and skeletal muscle), skeletal muscle was classified in 3 areas according to certain attenuations (i.e., NAMA, LAMA, and IMAT). Myosteatosis area was defined as the sum of LAMA and IMAT. IMAT, inter/intramuscular adipose tissue area; LAMA, low-attenuation muscle area; NAMA, normal-attenuation muscle area; SMA, skeletal muscle area; TAMA, total abdominal muscle area.
Figure 1. Example of body composition measurements. Muscle quality map generation using a web-based toolkit. After dividing body composition into 3 parts (i.e., subcutaneous fat, visceral fat, and skeletal muscle), skeletal muscle was classified in 3 areas according to certain attenuations (i.e., NAMA, LAMA, and IMAT). Myosteatosis area was defined as the sum of LAMA and IMAT. IMAT, inter/intramuscular adipose tissue area; LAMA, low-attenuation muscle area; NAMA, normal-attenuation muscle area; SMA, skeletal muscle area; TAMA, total abdominal muscle area.
Jcm 11 03031 g001
Jcm 11 03031 g002 550
Figure 2. Flowchart of patient enrollment and allocation in the study. DNR, do-not-resuscitation; CT, computed tomography.
Figure 2. Flowchart of patient enrollment and allocation in the study. DNR, do-not-resuscitation; CT, computed tomography.
Jcm 11 03031 g002
Jcm 11 03031 g003 550
Figure 3. Distribution of myosteatosis area (A–C) and percentage (D–F) according to the age groups in male, female, and total patients.
Figure 3. Distribution of myosteatosis area (A–C) and percentage (D–F) according to the age groups in male, female, and total patients.
Jcm 11 03031 g003
Table
Table 1. Baseline characteristics of the study population.
Table 1. Baseline characteristics of the study population.
CharacteristicsTotal
(n = 896)		Survivor
(n = 750)		Non-Survivor
(n = 146)		p-Value
Age67.0 (58.0–75.0)69.0 (60.0–76.0)63.5 (53.8–69.0)0.11
Male527 (58.8)433 (57.7)94 (64.4)0.14
Past illness
HTN299 (33.4)253 (33.7)46 (31.5)0.60
DM230 (25.7)195 (26.0)35 (24.0)0.61
CAD77 (8.6)69 (9.2)8 (5.5)0.14
Chronic pulmonary disease47 (5.2)34 (4.5)13 (8.9)0.03
Malignancy377 (42.1)303 (40.4)74 (50.7)0.02
Hematologic disorder58 (6.5)41 (5.5)17 (11.6)<0.01
CKD51 (5.7)45 (6.0)6 (4.1)0.37
LC139 (15.5)108 (14.4)31 (21.2)0.04
Site of infection
Unknown82 (9.2)67 (8.9)15 (10.3)0.61
Lung147 (16.4)112 (14.9)35 (24.0)<0.01
Urinary tract141 (15.7)127 (16.9)14 (9.6)0.03
Intra-abdomen141 (15.7)108 (14.4)33 (22.6)0.01
Hepato-biliary-pancreas358 (40.0)311 (41.5)47 (32.2)0.04
Blood stream66 (7.4)51 (6.8)15 (10.3)0.20
Lactate level3.6 (1.9–5.8)3.2 (1.7–5.4)5.4 (2.6–9.2)<0.01
SOFA score7.0 (5.0–10.0)7.0 (5.0–9.0)10.0 (6.0–13.0)<0.01
APACHE score15.0 (11.0–20.0)13.0 (11.0–23.0)17.0 (11.0–23.0)<0.01
Sarcopenia567 (63.3)474 (63.2)93 (63.7)0.91
Myosteatosis732 (81.7)607 (80.9)125 (85.6)0.19
Data are presented as n (%) or median (interquartile range). Abbreviations: HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; LC, liver cirrhosis; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation.
Table
Table 2. Body composition of the study population.
Table 2. Body composition of the study population.
Body CompositionTotal
(n = 896)		Survivor
(n = 750)		Non-Survivor
(n = 146)		p-Value
Total
BMI, kg/m222.2 (19.7–24.6)22.3 (19.7–24.6)21.9 (19.7–24.9)0.64
SFA, cm2107.3 (65.7–157.0)110.0 (66.6–157.2)94.9 (56.6–150.5)0.07
VFA, cm2101.0 (57.7–158.9)102.3 (57.4–160.4)90.9 (59.0–147.7)0.20
SMA, cm2106.2 (90.6–125.6)106.1 (89.8–126.7)106.7 (93.8–119.6)0.76
1 SMI, cm2/m240.6 (36.3–46.0)40.6 (36.3–46.4)41.0 (36.0–44.6)0.67
Normal attenuation MA, cm256.8 (37.8–78.4)57.4 (39.6–79.7)52.8 (32.8–69.6)<0.01
Intramuscular adipose tissue area, cm216.0 (9.6–23.2)16.3 (9.7–23.3)14.9 (9.2–22.6)0.42
Low attenuation MA, cm249.2 (36.8–60.9)47.6 (36.0–59.5)54.1 (42.7–66.4)<0.01
1 Total abdominal MA, cm2123.5 (109.2–142.1)123.2 (109.0–143.3)124.9 (109.9–136.2)0.59
2 Myosteatosis area, cm266.6 (47.5–84.1)65.9 (46.6–83.3)70.7 (55.2–90.5)0.03
3 Myosteatosis percentage, %0.53 (0.40–0.67)0.53 (0.39–0.66)0.57 (0.44–0.71)<0.01
Male
BMI, kg/m222.0 (19.7–24.4)22.1 (19.7–24.4)21.6 (20.0–24.4)0.63
SFA, cm287.7 (52.6–131.1)88.8 (55.8–131.3)83.9 (49.6–123.8)0.26
VFA, cm2110.1 (60.4–170.2)113.1 (59.0–171.7)97.2 (65.4–158.0)0.30
SMA, cm2118.9 (105.3–137.2)120.3 (106.2–138.3)114.4 (101.0–125.9)<0.01
1 SMI, cm2/m242.7 (38.5–49.3)42.8 (38.6–49.6)42.1 (37.4–46.0)0.07
Normal attenuation MA, cm270.2 (52.0–89.3)73.3 (54.3–92.2)60.3 (45.5–73.0)<0.01
Intramuscular adipose tissue area, cm214.9 (8.6–21.1)14.9 (8.7–21.1)14.0 (7.5–21.7)0.57
Low attenuation MA, cm250.0 (36.6–62.8)49.0 (35.3–62.6)53.8 (44.8–65.0)0.02
1 Total abdominal MA, cm2135.2 (120.4–152.6)138.4 (121.3–154.6)128.8 (115.1–144.7)<0.01
2 Myosteatosis area, cm265.9 (46.3–84.1)65.5 (45.7–83.5)67.0 (55.2–86.4)0.13
3 Myosteatosis percentage, %47.7 (35.1–60.2)46.1 (33.7–59.4)51.8 (40.5–66.2)<0.01
Female
BMI, kg/m222.6 (19.7–24.9)22.6 (19.7–24.8)22.4 (19.6–25.8)0.96
SFA, cm2137.8 (93.8–181.4)138.4 (95.6–181.4)124.9 (81.0–186.6)0.53
VFA, cm291.1 (53.8–133.0)91.7 (55.6–136.4)85.4 (33.3–130.1)0.27
SMA, cm290.6 (80.0–100.8)90.9 (80.3–100.4)89.3 (79.1–104.0)0.51
1 SMI, cm2/m237.9 (34.1–41.7)37.8 (33.9–41.5)37.9 (34.1–43.6)0.60
Normal attenuation AMA, cm241.0 (28.2–55.9)42.4 (28.6–56.0)33.7 (23.5–53.3)0.08
Intramuscular adipose tissue area, cm217.9 (12.0–25.7)18.0 (11.9–25.5)16.8 (12.6–27.0)0.71
Low attenuation MA, cm248.0 (36.9–58.7)46.5 (36.6–57.8)54.3 (40.6–66.6)<0.01
1 Total abdominal MA, cm2109.8 (98.8–121.7)109.3 (98.7–120.9)114.8 (99.1–127.7)0.29
2 Myosteatosis area, cm267.3 (49.4–84.3)66.8 (48.7–83.0)75.2 (54.0–95.2)0.13
3 Myosteatosis percentage, %61.5 (47.8–75.1)60.9 (47.3–74.6)69.1 (53.1–77.7)0.05
Data are presented as median (interquartile range). 1 Total abdominal MA was derived by adding the Normal attenuation MA, Intramuscular adipose tissue area, and Low attenuation MA. 2 Myosteatosis area was derived by adding the Low attenuation MA and Intramuscular adipose tissue area. 3 Myosteatosis proportion was defined as myosteatosis divided by Total abdominal MA. Abbreviations: BMI, body mass index; SFA, subcutaneous fat area; VFA, visceral fat area; SMA, skeletal muscle area; SMI, skeletal muscle area index; MA, muscle area.
Table
Table 3. Multivariate analysis of septic shock patients for its association with 28-day mortality.
Table 3. Multivariate analysis of septic shock patients for its association with 28-day mortality.
VariablesUnivariate AnalysisMultivariate Analysis
OR95% CIp-ValueAdjusted OR95% CIp-Value
Male
Age0.990.97–1.010.49
Intra-abdominal infection1.630.86–3.110.131.921.06–3.470.03
Hepato-biliary-pancreas infection0.710.41–1.240.71
Blood stream infection2.580.93–7.160.072.720.99–7.490.06
Lactate1.201.11–1.29<0.011.191.11–1.28<0.01
SOFA1.111.02–1.200.011.131.06–1.21<0.01
APACHE1.010.97–1.050.77
SMI0.960.94–0.990.020.960.93–0.980.03
myosteatosis percentage1.131.09–1.160.041.031.01–1.050.04
Female
Age0.990.96–1.020.60
Malignancy2.201.12–4.290.022.201.13–4.280.02
Lactate1.111.01–1.220.031.111.01–1.220.04
SOFA1.271.16–1.40<0.011.291.17–1.41<0.01
Myosteatosis percentage1.060.94–1.160.81
Abbreviations: OR, odds ratio; CI, confidence interval; CAD, coronary artery disease; CKD, chronic kidney disease; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kim, J.-s.; Ha, J.; Kim, Y.-J.; Ko, Y.; Park, T.; Kim, K.W.; Kim, W.Y. The Impact of Myosteatosis Percentage on Short-Term Mortality in Patients with Septic Shock. J. Clin. Med. 2022, 11, 3031. https://doi.org/10.3390/jcm11113031

AMA Style

Kim J-s, Ha J, Kim Y-J, Ko Y, Park T, Kim KW, Kim WY. The Impact of Myosteatosis Percentage on Short-Term Mortality in Patients with Septic Shock. Journal of Clinical Medicine. 2022; 11(11):3031. https://doi.org/10.3390/jcm11113031

Chicago/Turabian Style

Kim, June-sung, Jiyeon Ha, Youn-Jung Kim, Yousun Ko, Taeyong Park, Kyung Won Kim, and Won Young Kim. 2022. "The Impact of Myosteatosis Percentage on Short-Term Mortality in Patients with Septic Shock" Journal of Clinical Medicine 11, no. 11: 3031. https://doi.org/10.3390/jcm11113031

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop